Not all AI tools used in pharmacy are equivalent from a regulatory perspective. A chatbot that helps with grammar is not the same as software that provides clinical decision support for individual patients. A Q-bank that tests knowledge is not the same as a tool that recommends a specific drug for a specific patient. The MHRA recognises these distinctions — and pharmacists should understand them, both for their own practice and because regulatory awareness is part of the GPhC CRA assessment framework.
Why Pharmacists Should Understand AI Regulation
Pharmacists increasingly encounter AI across their practice: ambient scribes in GP consultations, clinical search tools for medicines queries, formulary aids for prescribing verification, calculation helpers during dispensing, exam Q-banks for CRA preparation, and general-purpose chatbots for clinical questions. Each has a different intended use, a different risk profile, and a different regulatory classification.
Understanding these distinctions helps pharmacists make informed decisions about which tools to trust for patient-facing clinical decisions, which to use cautiously as informational aids, and which require organisational governance approval before deployment in a clinical setting.
The Classification Framework
The MHRA says software, including AI, plays an essential role in health and social care, and that many software and AI products are regulated as medical devices in the UK. But not all software is a medical device.
General AI tools (ChatGPT, Claude, Gemini) are not designed specifically for clinical use. They can answer medical questions, but their manufacturer does not claim a specific medical purpose. They are not regulated as medical devices.
Clinical information and education tools are designed for healthcare professionals but positioned as informational or educational. Their intended use is to help professionals retrieve and understand information — not to provide patient-specific recommendations. The regulatory classification depends on the manufacturer's stated intended purpose.
Software as a medical device (SaMD) includes AI whose intended purpose is to inform, drive, or support clinical decisions about individual patients. The MHRA Software Group works on safety assurance for SaMD — including pre-market assessment, technical file reviews, post-market surveillance, clinical investigation review, and ensuring regulation is fit for software and AI.
The key principle: classification depends on intended use — what the manufacturer says the tool is designed to do — not on technical capability. A tool that could provide clinical decision support but is marketed for education has a different classification from one that claims to support patient-specific decisions.
Why Post-Market Surveillance Matters for AI
AI tools using machine learning or adaptive algorithms may change over time — updated models, retrained on new data, new features added. Post-market surveillance ensures continued safety and effectiveness. For regulated medical devices, this is mandatory. For unregulated tools, no such requirement exists.
Pharmacists should be aware that AI tools they use may change without notification. A tool that was accurate last month may behave differently after a model update. Ongoing verification — checking AI outputs against authoritative sources — is appropriate regardless of regulatory classification.
What Pharmacists Should Ask
What is the intended use? Education, information retrieval, or clinical decision support? What sources underpin the answers? Regulated SmPC data, peer-reviewed literature, or unspecified training data? Who remains accountable? The pharmacist — always. How are errors reported? Is there a clinical safety process? Is it registered with the MHRA? Class I or Class II registration indicates regulatory engagement — evidence of governance, though not a guarantee of accuracy.
Where Ask iatroX Fits
iatroX is UKCA-marked and MHRA-registered as a Class I medical device. It provides medicines information powered via eMC/SmPC alongside cited clinical answers. The intended use is clinical information support — the pharmacist retains responsibility for patient-specific decisions.
For pharmacists, the practical value is rapid access to regulated medicines and clinical information with visible provenance — not a transfer of professional accountability.
Try Ask iatroX — MHRA-registered, source-grounded clinical information for pharmacists →